Based in Cambridge, with a team of talented scientists, Dr Wilkinson is charged with the generation and delivery of novel candidate biotherapeutics. His team, uses the latest therapeutic strategies (incl. antibody and protein based platforms, oncolytic virotherapy and oligonucleotides) and is focused on immuno-oncology, as well as tumour targeted therapies, such as antibody-drug conjugates (ADCs). Molecules to come out of the group include the GITRL agonist, MEDI1873, and anti-PD-L1 antibody, Durvalumab, which is now in Phase III clinical trials in a range of cancer types.
Previously, Dr Wilkinson has held senior leadership roles with AstraZeneca and Imperial Cancer Research Fund Technology (now Cancer Research Technology) and received his PhD in Experimental Immunology from The University of Birmingham Medical School; and has co-authored over 50 publications in the field of drug discovery, immunology and cancer.